UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $197
Portfolio Pulse from Benzinga Newsdesk
UBS analyst A.J. Rice maintains a Buy rating on Tenet Healthcare (NYSE:THC) and raises the price target from $180 to $197.
August 14, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst A.J. Rice maintains a Buy rating on Tenet Healthcare and raises the price target from $180 to $197.
The raised price target and maintained Buy rating from a reputable analyst at UBS is likely to positively impact Tenet Healthcare's stock price in the short term as it reflects increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100